Calibrus

Calibr is a first-of-its-kind non-profit translational research institute that operates with the speed and efficiency of a biotechnology company. Founded in 2012 and merged with Scripps Research in 2016, the institute focuses on accelerating the transition of basic scientific discoveries into innovative medicines. Calibr manages a diverse pipeline spanning oncology, regenerative medicine, immunology, and infectious diseases, utilizing advanced modalities such as switchable CAR-T cell therapies and long-acting protein therapeutics. The organization leverages deep partnerships with pharmaceutical leaders and foundations to advance its programs through early-stage clinical trials.